

## S 3478

GAIN TOOLS Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Jan 11, 2022

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jan 11, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/3478>

### Sponsor

**Name:** Sen. Casey, Robert P., Jr. [D-PA]

**Party:** Democratic • **State:** PA • **Chamber:** Senate

### Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cassidy, Bill [R-LA]	R · LA		Jan 11, 2022
Sen. Murphy, Christopher [D-CT]	D · CT		Jan 11, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jan 11, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
117 HR 7667	Related bill	<b>Jun 9, 2022:</b> Received in the Senate.

## **Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022**

This bill expands the definition of a qualified infectious disease product (QIDP) to include eligible biological products. Under current law, the first application (or supplement) for a specific product and indication to be designated a QIDP shall receive priority review for market approval by the Food and Drug Administration.

Generally, a biological product designated as a QIDP is one that acts on bacteria or fungi and is intended to treat a serious or life-threatening infection.

However, a biological product with a QIDP designation shall not receive the market exclusivity extension currently available to drugs that receive the designation.

### **Actions Timeline**

---

- **Jan 11, 2022:** Introduced in Senate
- **Jan 11, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.